A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses.


Journal

PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755

Informations de publication

Date de publication:
06 2019
Historique:
received: 12 11 2018
accepted: 08 05 2019
entrez: 12 6 2019
pubmed: 12 6 2019
medline: 14 2 2020
Statut: epublish

Résumé

Rhino- and enteroviruses are important human pathogens, against which no antivirals are available. The best-studied inhibitors are "capsid binders" that fit in a hydrophobic pocket of the viral capsid. Employing a new class of entero-/rhinovirus inhibitors and by means of cryo-electron microscopy (EM), followed by resistance selection and reverse genetics, we discovered a hitherto unknown druggable pocket that is formed by viral proteins VP1 and VP3 and that is conserved across entero-/rhinovirus species. We propose that these inhibitors stabilize a key region of the virion, thereby preventing the conformational expansion needed for viral RNA release. A medicinal chemistry effort resulted in the identification of analogues targeting this pocket with broad-spectrum activity against Coxsackieviruses B (CVBs) and compounds with activity against enteroviruses (EV) of groups C and D, and even rhinoviruses (RV). Our findings provide novel insights in the biology of the entry of entero-/rhinoviruses and open new avenues for the design of broad-spectrum antivirals against these pathogens.

Identifiants

pubmed: 31185007
doi: 10.1371/journal.pbio.3000281
pii: PBIOLOGY-D-18-01199
pmc: PMC6559632
doi:

Substances chimiques

Amino Acids 0
Antigens, Viral 0
Antiviral Agents 0
Capsid Proteins 0
Viral Proteins 0
viral protein 1, rhinovirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3000281

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2
pubmed: 25199773
F1000Res. 2017 Oct 19;6:1860
pubmed: 29123648
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Virol J. 2015 Jul 14;12:106
pubmed: 26169596
Antiviral Res. 2014 Oct;110:1-9
pubmed: 25043639
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Science. 1986 Sep 19;233(4770):1286-93
pubmed: 3018924
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Sci Adv. 2016 Aug 24;2(8):e1501929
pubmed: 27574701
Clin Exp Vaccine Res. 2017 Jan;6(1):4-14
pubmed: 28168168
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):8997-9002
pubmed: 27511920
Antimicrob Agents Chemother. 2009 May;53(5):1850-7
pubmed: 19237651
J Virol. 2012 Dec;86(23):12571-81
pubmed: 22973031
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Vaccine. 2011 Dec 30;29 Suppl 4:D80-5
pubmed: 22486981
J Infect Dis. 2017 Feb 1;215(3):335-343
pubmed: 27932608
PLoS Pathog. 2014 Apr 10;10(4):e1004039
pubmed: 24722756
Antimicrob Agents Chemother. 1999 Sep;43(9):2109-15
pubmed: 10471549
Structure. 2008 May;16(5):673-83
pubmed: 18462672
Acta Crystallogr D Biol Crystallogr. 1995 Nov 1;51(Pt 6):871-87
pubmed: 15299757
J Struct Biol. 2015 Feb;189(2):114-22
pubmed: 25486611
J Virol. 2017 May 26;91(12):
pubmed: 28381577
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Nat Struct Biol. 2001 Oct;8(10):874-8
pubmed: 11573093
Bioorg Chem. 2015 Oct;62:74-82
pubmed: 26247308
Lancet Infect Dis. 2016 May;16(5):e64-e75
pubmed: 26929196
Nat Rev Microbiol. 2018 Jun;16(6):368-381
pubmed: 29626210
J Virol. 1985 Sep;55(3):560-6
pubmed: 2991580
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Rana Abdelnabi (R)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

James A Geraets (JA)

Faculty of Biological and Environmental Sciences, Molecular and Integrative Bioscience Research Programme, University of Helsinki, Helsinki, Finland.
Helsinki Institute of Life Sciences, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Yipeng Ma (Y)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Carmen Mirabelli (C)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Justin W Flatt (JW)

Faculty of Biological and Environmental Sciences, Molecular and Integrative Bioscience Research Programme, University of Helsinki, Helsinki, Finland.
Helsinki Institute of Life Sciences, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Aušra Domanska (A)

Faculty of Biological and Environmental Sciences, Molecular and Integrative Bioscience Research Programme, University of Helsinki, Helsinki, Finland.
Helsinki Institute of Life Sciences, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Leen Delang (L)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Dirk Jochmans (D)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Timiri Ajay Kumar (TA)

Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.

Venkatesan Jayaprakash (V)

Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.

Barij Nayan Sinha (BN)

Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.

Pieter Leyssen (P)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Sarah J Butcher (SJ)

Faculty of Biological and Environmental Sciences, Molecular and Integrative Bioscience Research Programme, University of Helsinki, Helsinki, Finland.
Helsinki Institute of Life Sciences, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Johan Neyts (J)

Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH